KR20140063861A - 조혈줄기세포 및 조혈전구세포의 생체 외 증식 방법 - Google Patents
조혈줄기세포 및 조혈전구세포의 생체 외 증식 방법 Download PDFInfo
- Publication number
- KR20140063861A KR20140063861A KR1020147010617A KR20147010617A KR20140063861A KR 20140063861 A KR20140063861 A KR 20140063861A KR 1020147010617 A KR1020147010617 A KR 1020147010617A KR 20147010617 A KR20147010617 A KR 20147010617A KR 20140063861 A KR20140063861 A KR 20140063861A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- picoline
- hpc
- hsc
- hematopoietic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 98
- 210000000130 stem cell Anatomy 0.000 title claims description 46
- 210000003958 hematopoietic stem cell Anatomy 0.000 title abstract description 229
- 239000003102 growth factor Substances 0.000 claims abstract description 72
- 101000885616 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 1 Proteins 0.000 claims abstract description 57
- 210000003995 blood forming stem cell Anatomy 0.000 claims abstract description 57
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 47
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 47
- 238000000338 in vitro Methods 0.000 claims abstract description 30
- 238000012258 culturing Methods 0.000 claims abstract description 23
- 239000001963 growth medium Substances 0.000 claims abstract description 22
- 230000012010 growth Effects 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 215
- 229910052760 oxygen Inorganic materials 0.000 claims description 112
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 103
- 239000001301 oxygen Substances 0.000 claims description 102
- 230000035755 proliferation Effects 0.000 claims description 92
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 67
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 66
- 210000004700 fetal blood Anatomy 0.000 claims description 48
- 230000001965 increasing effect Effects 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 40
- 210000001185 bone marrow Anatomy 0.000 claims description 38
- 230000003394 haemopoietic effect Effects 0.000 claims description 30
- 239000002609 medium Substances 0.000 claims description 24
- 108700014844 flt3 ligand Proteins 0.000 claims description 21
- 230000004069 differentiation Effects 0.000 claims description 17
- 239000010836 blood and blood product Substances 0.000 claims description 16
- 229940125691 blood product Drugs 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 210000002536 stromal cell Anatomy 0.000 claims description 15
- 230000004083 survival effect Effects 0.000 claims description 15
- 102000004889 Interleukin-6 Human genes 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 229940100601 interleukin-6 Drugs 0.000 claims description 13
- 102000036693 Thrombopoietin Human genes 0.000 claims description 12
- 108010041111 Thrombopoietin Proteins 0.000 claims description 12
- 238000012423 maintenance Methods 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 6
- 210000005259 peripheral blood Anatomy 0.000 claims description 6
- 239000011886 peripheral blood Substances 0.000 claims description 6
- 230000001902 propagating effect Effects 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 229940047122 interleukins Drugs 0.000 claims description 4
- 239000003636 conditioned culture medium Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 210000001541 thymus gland Anatomy 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 29
- 230000002062 proliferating effect Effects 0.000 abstract description 11
- 238000004113 cell culture Methods 0.000 abstract description 6
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 230000001332 colony forming effect Effects 0.000 description 31
- 210000000601 blood cell Anatomy 0.000 description 22
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 20
- 238000011534 incubation Methods 0.000 description 18
- 238000002054 transplantation Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 15
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 13
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 238000002512 chemotherapy Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 230000001186 cumulative effect Effects 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000010322 bone marrow transplantation Methods 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 210000003593 megakaryocyte Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 208000009329 Graft vs Host Disease Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 230000003021 clonogenic effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000024908 graft versus host disease Diseases 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- -1 50 ng / ml) Proteins 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000006501 Angiopoietin-like Proteins Human genes 0.000 description 3
- 108010019425 Angiopoietin-like Proteins Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000002629 repopulating effect Effects 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101100018264 Mus musculus Hoxb4 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100033051 40S ribosomal protein S19 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 101150005296 FCN1 gene Proteins 0.000 description 1
- 101150067835 FCN2 gene Proteins 0.000 description 1
- 102100024508 Ficolin-1 Human genes 0.000 description 1
- 102100024521 Ficolin-2 Human genes 0.000 description 1
- 102100024520 Ficolin-3 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101001052785 Homo sapiens Ficolin-1 Proteins 0.000 description 1
- 101001052753 Homo sapiens Ficolin-2 Proteins 0.000 description 1
- 101001052749 Homo sapiens Ficolin-3 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/59—Lectins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011903899A AU2011903899A0 (en) | 2011-09-22 | Cell culture & expansion | |
| AU2011903899 | 2011-09-22 | ||
| PCT/AU2012/001135 WO2013040644A1 (en) | 2011-09-22 | 2012-09-21 | Method for the ex vivo expansion of hematopoietic stem and progenitor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140063861A true KR20140063861A (ko) | 2014-05-27 |
Family
ID=47913674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147010617A Withdrawn KR20140063861A (ko) | 2011-09-22 | 2012-09-21 | 조혈줄기세포 및 조혈전구세포의 생체 외 증식 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9518250B2 (enExample) |
| EP (1) | EP2748309A4 (enExample) |
| JP (1) | JP6112462B2 (enExample) |
| KR (1) | KR20140063861A (enExample) |
| CN (1) | CN104114694A (enExample) |
| AU (1) | AU2012313347A1 (enExample) |
| CA (1) | CA2885665A1 (enExample) |
| IL (1) | IL231668A0 (enExample) |
| SG (1) | SG11201400851PA (enExample) |
| WO (1) | WO2013040644A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016178914A1 (en) * | 2015-05-01 | 2016-11-10 | Cesca Therapeutics, Inc. | Intramuscular adaminstration of autologous bone marrw for treatment |
| EP3313420B1 (en) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| EP3331993A1 (en) * | 2015-08-05 | 2018-06-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Use of dermatopontin for maintaining hematopoietic stem and/or progenitor cells in culture |
| US20200392533A1 (en) * | 2017-04-11 | 2020-12-17 | President And Fellows Of Harvard College | In vivo gene editing of blood progenitors |
| CN110093313B (zh) * | 2018-01-29 | 2023-04-14 | 华南生物医药研究院 | 促进造血干/祖细胞分化为红系细胞的诱导培养基及应用 |
| EP3836974A4 (en) | 2018-08-18 | 2022-06-15 | President and Fellows of Harvard College | IN SITU GENE EDIT |
| US20230212516A1 (en) * | 2020-06-02 | 2023-07-06 | Cornell University | Methods for expanding hematopoietic stem cells |
| CN115861151B (zh) * | 2021-09-23 | 2025-10-17 | 鸿海精密工业股份有限公司 | 细胞采收提醒方法及系统 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132017A1 (en) * | 1996-12-09 | 2002-09-19 | Moore Jeffrey G. | Composition and method for preserving progenitor cells |
| US20050137126A1 (en) * | 2003-04-09 | 2005-06-23 | Natlmmune A/S | Treatment of SARS in individuals |
| IL161903A0 (en) * | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
| US20060205071A1 (en) | 2003-07-17 | 2006-09-14 | Gamida-Cell Ltd. | Methods for ex-vivo expanding stem/progenitor cells |
| CN1297659C (zh) * | 2004-02-11 | 2007-01-31 | 上海伯瑞生物技术发展有限公司 | 一种造血细胞灌注培养方法和装置 |
| US7767453B2 (en) * | 2004-10-20 | 2010-08-03 | Whitehead Institute For Biomedical Research | Cultured hematopoietic stem cells and method for expansion and analysis thereof |
| KR20090009186A (ko) * | 2005-12-06 | 2009-01-22 | 디파트먼트 오브 바이오테크놀러지 | 사람의 조혈 줄기 세포 또는 선조 세포의 보존 방법 |
| JP2008237136A (ja) | 2007-03-28 | 2008-10-09 | Foundation For Biomedical Research & Innovation | ヒト造血細胞の培養方法 |
| WO2008149129A1 (en) | 2007-06-08 | 2008-12-11 | Nova Thera Limited | Cell expansion |
| CN101508975A (zh) * | 2009-03-26 | 2009-08-19 | 大连理工大学 | 一种低氧条件下微囊化成骨细胞支持和调控造血干/祖细胞体外扩增的方法 |
| WO2010142295A1 (en) * | 2009-06-10 | 2010-12-16 | Rigshospitalet | Ficolin-3 assay |
| US20120169643A1 (en) | 2009-09-09 | 2012-07-05 | Sharp Kabushiki Kaisha | Gesture determination device and method of same |
| CN102597223B (zh) * | 2009-09-11 | 2017-05-10 | 宝生物工程株式会社 | 生产天然杀伤细胞的方法 |
-
2012
- 2012-09-21 EP EP12832834.1A patent/EP2748309A4/en not_active Withdrawn
- 2012-09-21 AU AU2012313347A patent/AU2012313347A1/en not_active Abandoned
- 2012-09-21 CA CA2885665A patent/CA2885665A1/en active Pending
- 2012-09-21 CN CN201280052478.8A patent/CN104114694A/zh active Pending
- 2012-09-21 WO PCT/AU2012/001135 patent/WO2013040644A1/en not_active Ceased
- 2012-09-21 JP JP2014531047A patent/JP6112462B2/ja not_active Expired - Fee Related
- 2012-09-21 KR KR1020147010617A patent/KR20140063861A/ko not_active Withdrawn
- 2012-09-21 US US14/346,160 patent/US9518250B2/en not_active Expired - Fee Related
- 2012-09-21 SG SG11201400851PA patent/SG11201400851PA/en unknown
-
2014
- 2014-03-23 IL IL231668A patent/IL231668A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL231668A0 (en) | 2014-05-28 |
| AU2012313347A1 (en) | 2014-05-08 |
| JP2014527820A (ja) | 2014-10-23 |
| US9518250B2 (en) | 2016-12-13 |
| CA2885665A1 (en) | 2013-03-28 |
| SG11201400851PA (en) | 2014-04-28 |
| EP2748309A4 (en) | 2015-03-11 |
| CN104114694A (zh) | 2014-10-22 |
| EP2748309A1 (en) | 2014-07-02 |
| JP6112462B2 (ja) | 2017-04-12 |
| US20140286915A1 (en) | 2014-09-25 |
| WO2013040644A1 (en) | 2013-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Da Silva et al. | A human stromal-based serum-free culture system supports the ex vivo expansion/maintenance of bone marrow and cord blood hematopoietic stem/progenitor cells | |
| Li et al. | Human mesenchymal stem cells improve ex vivo expansion of adult human CD34+ peripheral blood progenitor cells and decrease their allostimulatory capacity | |
| US7927785B2 (en) | Methods for in vitro expansion of hematopoietic stem cells | |
| US10822589B2 (en) | Ex vivo NK cell differentiation from CD34+ hematopoietic cells | |
| KR20140063861A (ko) | 조혈줄기세포 및 조혈전구세포의 생체 외 증식 방법 | |
| US20040235160A1 (en) | Process for preparing hematopoietic stem cells | |
| Ehring et al. | Expansion of HPCs from cord blood in a novel 3D matrix | |
| Lo Iacono et al. | Wharton’s jelly mesenchymal stromal cells as a feeder layer for the ex vivo expansion of hematopoietic stem and progenitor cells: a review | |
| GB2455472A (en) | Structure enclosing hematopoietic progenitor cells from ES cells and method for preparing blood cells using the same | |
| WO2020076739A1 (en) | Methods for the long-term expansion of granulocyte-macrophage progenitors and applications thereof | |
| Yamaguchi et al. | Ex vivo expansion of human UC blood primitive hematopoietic progenitors and transplantable stem cells using human primary BM stromal cells and human AB serum | |
| Fei et al. | Co-culture of cord blood CD34+ cells with human BM mesenchymal stromal cells enhances short-term engraftment of cord blood cells in NOD/SCID mice | |
| US11236303B2 (en) | CD34+CD41DIM megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets | |
| Qu et al. | Endothelial progenitor cells promote efficient ex vivo expansion of cord blood–derived hematopoietic stem/progenitor cells | |
| CA2219869A1 (en) | Human cd-34 hematopoietic stem cells | |
| Romanov et al. | Human umbilical cord mesenchymal stromal cells support viability of umbilical cord blood hematopoietic stem cells but not the “stemness” of their progeny in co-culture | |
| Kim et al. | Generation of CD34+ cells from human embryonic stem cells using a clinically applicable methodology and engraftment in the fetal sheep model | |
| US20060084170A1 (en) | Cytokine-free growth and maintenance of progenitor cells | |
| Takeda et al. | CD318/CUB-domain-containing protein 1 expression on cord blood hematopoietic progenitors | |
| Ookura et al. | Adipocyte differentiation of human marrow mesenchymal stem cells reduces the supporting capacity for hematopoietic progenitors but not for severe combined immunodeficiency repopulating cells | |
| Mizokami et al. | Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells | |
| KR101149007B1 (ko) | 생착능이 증가된 조혈줄기세포의 제조방법 | |
| KR100702862B1 (ko) | 제대혈 유래 간엽줄기세포를 세포영양막으로 이용한조혈모세포/전구세포의 체외 성장 및 증식방법 | |
| KR100999905B1 (ko) | 생착능이 증가된 조혈줄기세포의 제조방법 | |
| Yasuhisa et al. | Derivation of functional mature neutrophils from human embryonic stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20140421 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PN2301 | Change of applicant |
Patent event date: 20160830 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170912 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20171019 |
|
| WITB | Written withdrawal of application |